Corixa Transfers Bexxar to GlaxoSmithKline

Corixa, original developer of Bexxar(R), the novel NHL drug, has transferred its rights to the drug to GlaxoSmithKline, it's manufacturing partner.

The change should not affect Bexxar availability but Corixa laid off 160 employees right before the holidays.

This blog will continue to dig the dirt on this situation as it unfolds.

Press Release

LymphomaInfo Social